Image Source: Zacks Investment Research Earlier this month, privately-held Boehringer Ingelheim said it would cap out-of-pocket expenses for all its inhaler products at $35 per month beginning in ...

He pointed to Boehringer Ingelheim’s decision to drop list prices on Spiriva HandiHaler, an older inhaler that now faces ...

The heritage of Boehringer Ingelheim in developing medicines for ... We are building upon our strong heritage in bronchodilator and inhaler development with ongoing clinical development programmes ...

The Hailie Smartinhaler device has also been cleared for use with inhalers from other manufacturers, including GSK, Boehringer Ingelheim, and Teva, and Adherium also sells the device directly to ...

Medscape Medical News, March 07, 2024 Boehringer to Cap Out-of-pocket Inhaler Cost At $35 Per Month Boehringer Ingelheim will cap out-of-pocket costs for the company's inhaler products for a ...

Boehringer to cap out-of-pocket inhaler cost at $35 per month Boehringer Ingelheim will cap out-of-pocket costs for the company's inhaler products for a chronic lung disease and asthma at $35 per ...

As of June 1, 2024, companies such as Boehringer Ingelheim and AstraZeneca capped the out-of-pocket price of their inhalers for COPD and asthma. For Boehringer Ingelheim, this includes Stiolto ...